Filtered By:
Specialty: Hematology
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 677 results found since Jan 2013.
Impact of double‐blind versus open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis
ConclusionsOur meta‐analysis showed no significant interaction of study design for the main efficacy and safety outcomes. However, the non‐significantly exaggerated reduction in SSE suggests interdependence of treatment effect and PROBE design, especially for haemorrhagic stroke.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - May 9, 2013 Category: Hematology Authors: Jean‐Christophe Lega, Patrick Mismetti, Michel Cucherat, Thomas Fassier, Laurent Bertoletti, Céline Chapelle, Silvy Laporte Tags: Original Article ‐ Cardiovascular Medicine Source Type: research
Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta‐analysis of risk‐modifying drugs
ConclusionsAge, female sex, AF, hypertension, diabetes, myocardial infarction, heart failure and stroke are most common risk factors for thromboembolectomy of the upper limb. The availability of new OACs holds promise for reducing the risk of systemic thromboembolism, but specific data are still limited.
Source: Journal of Thrombosis and Haemostasis - May 15, 2013 Category: Hematology Authors: L. V. Andersen, G. Y. H. Lip, J. S. Lindholt, L. Frost Tags: Original Article Source Type: research
Impact of double‐blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta‐analysis
ConclusionsOur meta‐analysis showed no significant interaction of study design for the main efficacy and safety outcomes. However, the non‐significantly exaggerated reduction in SSE suggests interdependence of treatment effect and PROBE design, especially for hemorrhagic stroke.
Source: Journal of Thrombosis and Haemostasis - July 15, 2013 Category: Hematology Authors: J.‐C. Lega, P. Mismetti, M. Cucherat, T. Fassier, L. Bertoletti, C. Chapelle, S. Laporte Tags: Original Article Source Type: research
D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial
ConclusionIn anticoagulated patients with AF the level of D‐dimer is related to the risk of stroke, death and bleeding and adds to the predictive value of clinical risk scores. The benefits of apixaban were consistent regardless of the baseline D‐dimer level.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 18, 2014 Category: Hematology Authors: Christina Christersson, Lars Wallentin, Ulrika Andersson, John H Alexander, Jack Ansell, Raffaele Caterina, Bernard J Gersh, Christopher B Granger, Michael Hanna, John D Horowitz, Kurt Huber, Steen Husted, Elaine M Hylek, Renato D Lopes, Agneta Siegbahn Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation - observations from the ARISTOTLE trial.
CONCLUSION: In anticoagulated patients with AF the level of D-dimer is related to the risk of stroke, death and bleeding and adds to the predictive value of clinical risk scores. The benefits of apixaban were consistent regardless of the baseline D-dimer level. This article is protected by copyright. All rights reserved.
PMID: 24942912 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 18, 2014 Category: Hematology Authors: Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A Tags: J Thromb Haemost Source Type: research
Predictors of Anticoagulant Treatment in Patients With Nonvalvular Atrial Fibrillation: Results From Atrial Fibrillation in Turkey: Epidemiologic Registry
In this study, we demonstrated that stroke history, persistent/permanent AF, hypertension, DM, and left atrial diameter were positive predictors, whereas advanced age and heart failure were negative predictors of oral anticoagulant use in patients with nonvalvular AF.
Source: Clinical and Applied Thrombosis/Hemostasis - February 2, 2015 Category: Hematology Authors: Kaya, H., Ertaş, F., Koroğlu, B., Vatan, B., Cağlıyan, C. E., Gedik, S., Yeter, E., Aydin, M., Akil, M. A., Soydinc, M. S., Ozhan, H., Ulgen, M. S., for the AFTER Investigators Tags: Original Articles Source Type: research
Comparative Efficacy and Safety of the Non–Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation
Semin Thromb HemostDOI: 10.1055/s-0035-1544156The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor (dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have been shown to be at least as efficacious and safe as conventional oral anticoagulants, such as the vitamin K antagonists (VKAs) (e.g., warfarin), for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Each NOAC has various advantages and specific features, and therefore decisions regarding appropriate stroke prevention require individual assessment of stroke and bleeding ri...
Source: Seminars in Thrombosis and Hemostasis - February 15, 2015 Category: Hematology Authors: Senoo, KeitaroLip, Gregory Y. H. Source Type: research
The role of soluble fibrin during anticoagulant therapy: a case report
We present the case of a 70-year-old male patient with persistent NVAF who developed pulmonary thromboembolism (PTE), deep vein thrombosis (DVT), and left atrial thrombus during anticoagulant therapy with warfarin. Intravenous recombinant tissue plasminogen activator was administered during his acute PTE. Heparin and apixaban were administered over 28 days; heparin was discontinued after the DVT resolved, while apixaban was administered to prevent ischemic stroke. Two days after heparin was discontinued, the patient experienced an ischemic stroke. Dabigatran was administered for secondary ischemic stroke prevention. Solub...
Source: Thrombosis Journal - July 6, 2015 Category: Hematology Authors: Tohru KawakamiNobukiyo TanakaHiroki IshiharaHiroyoshi Ohno Source Type: research
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
In conclusion, compared with warfarin, dabigatran treatment was associated with a lower risk of stroke and most outcomes measured, but increased incidence of major lower GI bleeding.
PMID: 26446456 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 8, 2015 Category: Hematology Authors: Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E Tags: Thromb Haemost Source Type: research
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.
We examined baseline levels of D-dimer and their association with stroke, cardiovascular death and major bleeding in 6,202 AF patients randomised to dabigatran or warfarin in the RE-LY trial. The effects of treatment on serial levels of D-dimer and coagulation factor (F) VIIa in 2,567 patients were also analysed. Baseline D-dimer levels were related to the rate of stroke/systemic embolism (SEE) with 0.64 % in the lowest quartile (Q1, as reference) (D-dimer < 298 µg/l), 1.38 % Q2 (D-dimer 298-473 µg/l), 1.71 % Q3 (D-dimer 474-822 µg/l) and 2.00 % in Q4 (D-dimer > 822 µg/l) (p=0.0007). Similar associati...
Source: Thrombosis and Haemostasis - January 28, 2016 Category: Hematology Authors: Siegbahn A, Oldgren J, Andersson U, Ezekowitz MD, Reilly PA, Connolly SJ, Yusuf S, Wallentin L, Eikelboom JW Tags: Thromb Haemost Source Type: research
Dabigatran Versus Warfarin in Atrial Fibrillation: Multicenter Experience in Turkey
Safety issues have been raised about dabigatran. We aimed to investigate the occurrence of safety outcomes in patients who had atrial fibrillation and a risk of stroke. We analyzed 439 patients prescribed dabigatran (n = 220) or warfarin (n = 219). Ischemic stroke occurred in 15 (6.8%) patients in the warfarin group versus 5 (5.2%) patients in the 110-mg group versus 1 (0.8%) patient in the 150-mg dabigatran group (P = .015). Intracranial hemorrhage occurred in 6 (2.7%) patients in the warfarin group versus 3 (2.4%) patients in the 150-mg dabigatran group (P = .104). Death from any cause occurred in 10 (4.6%) patients in t...
Source: Clinical and Applied Thrombosis/Hemostasis - February 2, 2016 Category: Hematology Authors: Aslan, O., Yaylali, Y. T., Yildirim, S., Yurtdas, M., Senol, H., Ugur-Yildiz, M., Ozdemir, M. Tags: Original Articles Source Type: research
Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation
Atrial fibrillation (AF) is a significant risk factor for stroke and peripheral thromboembolic events (TEs). Preventing blood clots in the heart to reduce stroke and TE risk is a key goal of AF therapy. Traditional stroke risk assessment tools for patients with nonvalvular AF include the CHADS2 and CHA(2)DS(2)-VASc scores, while long-term outcome data with the newer direct oral anticoagulants (DOACs) are emerging. The goals of this review were to assess traditional therapies and existing treatment guidelines and to discuss key pharmacologic properties of the DOACS, noting how these may benefit at-risk patients with AF. Thi...
Source: Clinical and Applied Thrombosis/Hemostasis - November 27, 2016 Category: Hematology Authors: Stacy, Z., Richter, S. Tags: Review Source Type: research
Anticoagulants Resumption after Warfarin-Related Intracerebral Haemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy (MUCH-Italy).
In conclusion, in patients who have an ICH while receiving warfarin, resuming anticoagulation results in a favorable trade-off between bleeding susceptibility and thromboembolic risk.
PMID: 29433151 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 12, 2018 Category: Hematology Authors: Poli L, Grassi M, Zedde M, Marcheselli S, Silvestrelli G, Sessa M, Zini A, Paciaroni M, Azzini C, Gamba M, Toriello A, Tassi R, Giorli E, Calabrò RS, Ritelli M, De Vito A, Pugliese N, Martini G, Lanari A, Lodigiani C, Padroni M, De Giuli V, Caria F, Moro Tags: Thromb Haemost Source Type: research
Real World Experience of Direct Oral Anticoagulants with Comparison of Safety Outcomes to the Warfarin Era of Venous Thromboembolism Treatment
Conclusion:This retrospective audit shows that our local safety outcomes are comparable to clinical trials. Low dose anticoagulation and high falls risk (a surrogate marker of frailty) were significant risk factors for both clinically significant bleeding and thrombotic stroke in the DOAC population. These patients are likely frailer with greater co-morbidities and have shared risk factors for bleeding and stroke, suggesting that for these high risk patients, low dose anticoagulation does not negate their risk of complications and careful prescribing and close monitoring remain essential.The sub-comparison between VTE pati...
Source: Blood - November 21, 2018 Category: Hematology Authors: Brook, R., Aswapanyawongse, N., Lim, H. Y., Ho, P. Tags: 331. Pathophysiology of Thrombosis: Poster II Source Type: research
Indications, Efficacy and Complications of Kcentra Use in Reversing Coagulopathy
ConclusionsKcentra was used in several off-label clinical settings, with comparable mortality among the coumadin, rivaroxaban and apixaban groups and no identifiable benefit in the setting of cirrhosis, DIC or antiplatelet medications, but with an increased incidence of deep vein thrombosis and stroke.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Sritharan, N., Triulzi, D. Tags: 401. Basic Science and Clinical Practice in Blood Transfusion: Poster III Source Type: research
